Clinical Trial

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

Name: Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） — clinical trial record (NCT07104617)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy

Trial Details

NCT Number	NCT07104617
Lead Sponsor	TYK Medicines, Inc
Conditions	Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment	48 participants
Start Date	2025-08
Primary Completion	2026-10 (estimated)
Study Completion	2026-11 (estimated)
Updated on ClinicalTrials.gov	2025-08-05